Business UpdateMay 28, 2026, 08:02 AM
Artiva Management to Present at Jefferies Global Healthcare Conference
AI Summary
Artiva Biotherapeutics announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 9:20 am EDT. The company, a clinical-stage biotechnology firm, is focused on developing effective, safe, and accessible cell therapies for patients with debilitating autoimmune diseases. Its lead program, AlloNK (AB-101), is currently being evaluated in three ongoing clinical trials for B-cell driven autoimmune diseases, with plans to initiate a Phase 3 registrational trial in refractory RA in 2026.
Key Highlights
- Artiva management to participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference.
- The presentation is scheduled for Thursday, June 4, 2026, at 9:20 am EDT.
- An audio webcast and archived recording will be available on Artiva's investor website for 90 days.
- Artiva is a clinical-stage biotechnology company developing cell therapies for autoimmune diseases.
- Its lead program, AlloNK (AB-101), is an allogeneic, off-the-shelf NK cell therapy candidate.
- AlloNK is currently being evaluated in three ongoing clinical trials for B-cell driven autoimmune diseases.
- Artiva plans to initiate a Phase 3 registrational trial for AlloNK in refractory RA in 2026.
Price Impact
More from ARTV